BioNTech (BNTX) R&D Day summary

Pipeline overview and program updates

• Over 20 ongoing phase II and III oncology trials and more than 30 novel combination cohorts across tumor types, with a focus on multi-platform oncology and infectious disease pipelines.

• The pipeline includes immunomodulators (notably pumitamig and gotistobart), ADCs, mRNA cancer immunotherapies, and individualized neoantigen-specific therapies, spanning solid tumors, breast, lung, GI, GU, and gynecologic cancers.

• Strategic pivot back to oncology post-COVID, emphasizing immunomodulators, ADCs, and mRNA cancer immunotherapies, with a disease area-specific approach planned for 2026.

• Three-wave clinical strategy: foundational registration trials, expansion into additional indications, and novel combination therapies.

• Key partnerships with BMS, DualityBio, MediLink, Genentech, and OncoC4 support pipeline breadth and depth.

Clinical trial data and development milestones

• Pivotal phase III trials for pumitamig in NSCLC, SCLC, TNBC, CRC, and gastric cancer are ongoing, showing efficacy across PD-L1 statuses and in combination with chemotherapy and ADCs.

• Gotistobart, a differentiated anti-CTLA-4 antibody, is advancing in phase 3 for 2L squamous NSCLC, with data to be presented at NACLC in December 2025.

• ADCs such as trastuzumab pamirtecan and BNT324/DB-1311 have demonstrated encouraging activity in HER2-expressing and B7-H3-expressing tumors, respectively.

• mRNA immunotherapies (FixVac, iNeST) are being evaluated in randomized trials, with autogene cevumeran showing robust, durable T-cell responses in melanoma and CRC.

• Multiple pivotal and proof-of-concept trials are ongoing or planned, with key data readouts expected in 2025 and 2026.

R&D strategy and innovation priorities

• Emphasis on combination therapies, including IO backbones, ADCs, and mRNA immunotherapies, to address tumor heterogeneity and resistance.

• In-house ADC capabilities target improved linker technology and new modes of action, with ongoing innovation cycles.

• Full AI integration and in-house manufacturing enable rapid, personalized drug development and clinical execution.

• Portfolio management prioritizes high-probability, late-stage assets while maintaining investment in high-risk, high-reward programs.

• mRNA platform leveraged for both off-the-shelf and individualized cancer vaccines, emphasizing innate immune activation.